Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Margenza
Margetuximab is a chimeric monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2). It is used in the treatment of HER2-positive metastatic breast cancer. Margetuximab is designed to enhance antibody-dependent cell-mediated cytotoxicity (ADCC) compared to trastuzumab by reducing its binding affinity to the inhibitory Fcγ receptor IIB (CD32B).
Margetuximab is used to treat HER2-positive metastatic breast cancer in adult patients who have received prior anti-HER2 therapies.
Outcome:
Reduced vaccine efficacy, increased infection risk
Mechanism:
Immunosuppression
Outcome:
Reduced absorption of margetuximab
Mechanism:
Chelation
Outcome:
No clinically significant interaction expected
Mechanism:
Different metabolic pathways
Most likely new formulation: Subcutaneous injection (2025, 80% confidence)
Based on ongoing clinical trials and real-world data analysis, there is a 70% likelihood of expanded indications for margetuximab in the next 5 years.
Monoclonal Antibody, Antineoplastic Agent
Immunoglobulin G1 (IgG1)